AdAlta Company Description

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia.

The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases.

The company was incorporated in 2006 and is based in Hawthorn East, Australia.

AdAlta Limited

Country	Australia
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Timothy Oldham

Contact Details

Address: 117 Camberwell Road Hawthorn East, VIC 3123 Australia
Phone	61 3 9479 5159
Website	adalta.com.au

Stock Details

Ticker Symbol	1AD
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000001AD2
SIC Code	2836

Key Executives

Name	Position
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.	Chief Executive Officer, MD and Director
Angus Tester Ph.D.	Senior Director of Operations
Prof. Michael Foley Ph.D.	Founding Chief Scientist
Dr. Andrew Peter O'Brien MBA., Ph.D.	Head of Corporate Development
Janette Dixon	Head of Business Development
Dr. Kevin Patrick Lynch FFPM, M.D., MBBS	Consultant Chief Medical Officer of Oncology
Cameron Peter Jones C.A.	Company Secretary